drugset / Trial / NCT06887803
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.
Timeline
- Start
- 2025-11-17
- Primary completion
- 2028-03
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | roginolisib | Small molecule | 72 mg | — |
| Background | Ruxolitinib | Small molecule | 25 mg | — |